Change in muscle volume after steroid therapy in patients with myositis assessed using cross-sectional computed tomography

Table 2 Profiles of the patients in the control group

Patient	Age (years)	Sex	Diagnosis	Max glucocorticoid (mg/day)^a	Duration between the start of treatment and second CT (months)^b	Dose of glucocorticoid at second CT (mg/day)	Cumulative doses of glucocorticoid (g)^c,d
1	70	M	MCNS	PSL: 40	1.5	PSL: 25	PSL: 1.4
2	66	F	LN	mPSL → PSL: 35	2.5	PSL: 20	PSL: 2.4
3	46	F	LN	mPSL → mPSL: 32	3	mPSL: 12	PSL: 2.2
4	57	F	EPGA	mPSL → PSL: 50	3	PSL: 25	PSL: 3.4
5	80	M	MPA	mPSL → PSL: 30	2.5	PSL: 15	PSL: 1.3
6	86	F	MPA	mPSL → mPSL: 32	1.5	mPSL: 20	PSL: 1.5
7	79	F	MCNS	mPSL: 32	1.5	mPSL: 16 + PSL: 2	PSL: 1.6
8	76	F	HSPN	mPSL: 32	5.0	mPSL: 8	PSL: 2.6

M male, F female, MCNS minimal change nephrotic syndrome, LN lupus nephritis, EPGA eosinophilic granulomatosis with polyangiitis, MPA microscopic polyangiitis, HSPN Henoch-Schönlein purpura nephritis, PSL prednisolone, mPSL methylprednisolone
^aInitial mPSL dose was 500 mg × 3 d, except for Patient 3 (1 g × 3 d) and Patients 7 and 8 (reported in table)
^bThe first CTs were performed within 6 weeks before the initial steroid therapy
^cSteroid taken using steroid pulse was excluded from cumulative doses of glucocorticoid
^dmPSL 0.8 mg is converted as PSL 1 mg

ISSN: 1471-2474